Hans Biomed Corp · KRX:042520
Hans Biomed — Investor Presentation (January 2024)
29 slides from Hans Biomed's investor presentation, Jan 23, 2024
Slide 1: HansBiomed Corp. Investor Relations 2024
HansBiomed Corp. Investor Relations 2024 ⓒSaebyeol Yu. Saebyeol’s PowerPoint
Slide 2: Disclaimer
Disclaimer This material has been prepared by HansBiomed Corp.(the “Company”) for the purpose of providing information in a Presentation that will be made for investors. Please be informed that transferring, copying, or re-distributing this document to others is prohibited. Attendance at this presen
Slide 3: Chapter 01. About Us
Chapter 01. About Us 1) Company Overview 1-1 Introduction 1-2 History 1-3 Infrastructure 1-4 Corporate governance 2) Product Portfolio ⓒSaebyeol Yu. Saebyeol’s PowerPoint
Slide 4: Company Overview: Introduction
Chapter 01_01 Company Overview_Introduction HansBiomed Corp. A leader in tissue engineering and plastic surgery medical devices in Korea A leader in the global bio industry Company Name HansBiomed Corp. Date Established September 15, 1999 CEO GeunYoung Kim Business Areas Development, manufacturing,
Slide 5: Company Overview: History
Chapter 01_01 Company Overview_History A Company that creates unprecedented innovation based on innovation R&D technology Steady Make Development Establish Innovations Technology 2008 Gained CE certification(Europe)for breast 2019 Established a GMP manufacturing facility Established HansMedical for
Slide 6: Company Overview: Infrastructure
Chapter 01_01 Company Overview_Infrastructure HansBiomed GMP HansBiomed Lab Location In Daejeon Location In Daejeon Established In 2002 Established In 2019 GMP Tissue / Silicone / R&D High-Technology Medical devices Biopharmaceuticals R&D First Tissue Bank GMP GMP Facility in Korea AATB Accreditaion
Slide 7: Company Overview: Corporate governance
Chapter 01_01 Company Overview_Corporate governance Hans USA HansPhama Shareholder Sturcture of HansBiomed Employeesㅣ40 Employees ㅣ26 Establishedㅣ2011 Established ㅣ2015 Shares Ratio ① ①Founder & Affiliated 3,407,196 25.18% Hans person Thailand Mint Medical ② ②Treasury shares 539,388 3.99% Employees
Slide 8: Product Portfolio
Chapter 01_02 Product Portfolio *Unit : KRW 100million Biologics 25th Sales(%) 24th Sales(%) Medical Device 25th Sales(%) 24th Sales(%) Silicone Polymer 37,201 32,292 (47%) (43%) Biocosmetic 34,154 35,121 25th Sales(%) 24th Sales(%) (44%) (47%) 1,095 1,894 25th Sales(%) 24th Sales(%) Bone graft (1%)
Slide 9: Chapter 02. Business areas
Chapter 02. Business areas 1) Biologics 1-1 Bone graft 1-2 Skin graft 1-3 Sales analysis 1-4 Chinese market 2) Medical device 2-1 Lifting thread (MINT LIFT) 2-2 Hair transplant device (LION) 3) Biocosmetic 3-1 Cosmeceutical (Kladie) 4) Silicon Polymer ⓒSaebyeol Yu. Saebyeol’s PowerPoint
Slide 10: Biologics: Bone graft
Chapter 02_01 Biologics _ Bone graft SureOss® ExFuseTM GenesisTM Sponge OSSTOP™ • It is a freeze-fried allgenic bone of • It is a DBM plus cancellous bone • Sponge-type allograft with • Absorbable and hemostatic agent cortical bone that does not under chip, which stimulates the go demineralization,
Slide 11: Increasing Sales of Dental Bonegraft
Chapter 02_01 Biologics _ Bone graft Increasing Sales of Dental Bonegraft HansBiomed Allograft(Bone) •Used for gum reconstruction during dental (Unit : KRW 100million) Dental Bonegraft Sales Trend implant surgery •Certified by MFDS(Korea), FDA 510K(US), 140 NMPA(China) and others 121.51 120.84 120 1
Slide 12: Biologics: Skin graft
Chapter 02_01 Biologics _ Skin graft BellaCell HD™ SureDerm™ UROMAX SureDerm® Implant BellaGen™ • Non-cellular allograft used in • Non-cellular allograft used in • Used in OS and NS for ligaments • It is an injectable ADM product breast surgery and other urology and skin defects made of 100% allogen
Slide 13: BellaCell HD
Chapter 02_01 Biologics _ Skin graft Promotion of rapid growth for BellaCell HD Develop New ADM Market •GS, PS Breast Conserving Surgery (Used for reconstruction surgeries such as breast cancer) (Unit : KRW 100million) BellaCell HD Sales Trend •NS Crainotomy of using ADM (After neurosurgery cranial
Slide 14: Biologics: Sales analysis
Chapter 02_01 Biologics _ Sales analysis Biologics Sales Trend 25th Sales Analysis (Unit : KRW 100million) 400 372.01 350 322.92 300 Overseas 248.32 BONE Domestic 250 209.87 15% BONE/SKIN(OSSTEM) 205.97 200 Domestic 25% 179.08 166.04 BONE 150 15% 113.05 100 Overseas 69.24 SKIN Domestic 50 6% SKIN 39
Slide 15: Biologics: Chinese Market
Chapter 02_01 Biologics _ Chinese Market 50% Equity Investment 50% Rebirth Equity Biotechnology Investment (LCC) WEGO GROUP HansBiomed Corp. • Manufacturer and distributor of medical • Scheduled to complete a production facility in Qingdao, • A cash investment of 20 million yuan(KRW devices China 3.
Slide 16: Biologics: Chinese Market
Chapter 02_01 Biologics _ Chinese Market 15 15 ⓒSaebyeol Yu. Saebyeol’s PowerPoint
Slide 17: MINT Lift
Chapter 02_02 Medical device_ Lifting thread 360° HELICAL DESIGN lifting thread MINT Lift® • Certified by MFDS(Korea), FDA(US), CE(Europe), NMPA(China) and others in 11 countries • Being sold by export to 40+ countries • 100% biodegradable polydioxanone (PDO) component absorbed in the dermis layer •
Slide 18: MINT Lift: 360° helical design
Chapter 02_02 Medical device_ Lifting thread 360° HELICAL DESIGN lifting thread MINT Lift® 360° HELICAL DESIGN During the press-molding process, the barbs are positioned in a 360° helical pattern around the MINT Lift threads. This design allows the MINT • Manufacturing method patented in 11 countrie
Slide 19: MINT Lift Sales Trend by Country
Chapter 02_02 Medical device_ Lifting thread (Unit : KRW 100million) MINT Lift® Sales Trend by Country 350 325.46 316.81 300 250 227.01 200 164.81 150 137.35 140.52 107.35 100 79.14 49.22 65.48 74.54 74.08 78.67 62.06 46.27 50.81 50 22.98 38.61 41.86 17.55 20.63 23.54 0 0 6.79 0 21th 22th 23th 24th
Slide 20: All about Lifting thread
Chapter 02_02 Medical device_ Lifting thread All about Lifting thread Purchase and education at once! One stop service is opened MintLift Specialty Global Online Shop Medical Professional The Library Education Platform of Lifting Thread • An integrated shop where you can purchase • Real-time webinar
Slide 21: Patented hair transplant device, LION
Chapter 02_02 Medical device_ Hair transplant device Patented hair transplant device, LION LION Sales Trend (Unit : KRW 100million) 25 22.07 20 17.29 15 14.9 12.56 10 • Lion is a hair transplant device approved in more than 10 countries, including the USA(FDA) and Korea(MFDS) 5 • Patented clips allo
Slide 22: Cosmeceutical: Bio-Cosmetic brand, Klardie
Chapter 02_03. Cosmeceutical Bio-Cosmetic brand, Klardie Klardie technologies Continuous research on ‘Human umbilical cord-derived mesenchymal stem cell(hUC-MSCs)’ ▶Found positive rusults in terms of skin cell regeneration, whitening, and antioxidant Skinbooster Scalp-repair Cellup Ampoule ▶ R&D of
Slide 23: Silicon Polymer
Chapter 02_04. Silicon Polymer Breast Implant, BellaGel • The first artificial breast implants brand to developed exclusively in Korea • An issue with BellaGel emerged in 2020 • Operation of the BellGel CS Center - Ran an integrated website for compensation and long-term monitoring - 1.83 billion KR
Slide 24: Chapter 03. Growth strategy
Chapter 03. Growth strategy 1) Future growth engine ⓒSaebyeol Yu. Saebyeol’s PowerPoint
Slide 25: Future Growth Engine
Chapter 03_01. Future Growth Engine R&D Center of R&D Center of Tissue Engineering Advanced medical devices R&D of non-absorbable lifting thread Process improvement and R&D of automation R&D of bone hemostat R&D of human tissue-based new product R&D of tendon ECM injection R&D of MINT Lift’s new pro
Slide 26: Chapter 04. Business Performance & ESG
Chapter 04. Business Performance & ESG 1) Business performance and Forecast 2) ESG ⓒSaebyeol Yu. Saebyeol’s PowerPoint
Slide 27: Sustainable growth of sales and generation of profit
Chapter 04_01. Business performance and Forecast GOAL : Sustainable growth of sales and generation of profit (Unit : KRW 1won) 80.1B 80B 800 78B 74.5B 67B 59.1B 60B 600 40B 400 Sales OP 20B 200 12.6B 1.3B 00 -3.4B -4.1B -19.7B -20B -200 21th 22th 23th 24th 25th 26th(E) (2019) (2020) (2021) (2022) (2
Slide 28: ESG
Chapter 04_02. ESG CSR Carbon neutrality Compliance Declaration of ethical management to Use eco-friendly paper and ink minimize the risk of management Quarterly employee volunteering and packaging corruption donation activities to contribute to the Participation in the Ministry of Implementation of
Slide 29: Thank You
Thank You ⓒSaebyeol Yu. Saebyeol’s PowerPoint